Protein Kinases Mediate Anti-Inflammatory Effects of Cannabidiol and Estradiol Against High Glucose in Cardiac Sodium Channels by Fouda, Mohamed A. & Ruben, Peter C.
Protein Kinases Mediate
Anti-Inflammatory Effects of
Cannabidiol and Estradiol Against
High Glucose in Cardiac Sodium
Channels
Mohamed A. Fouda1,2 and Peter C. Ruben1*
1Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada, 2Department of
Pharmacology and Toxicology, Alexandria University, Alexandria, Egypt
Background: Cardiovascular anomalies are predisposing factors for diabetes-induced
morbidity and mortality. Recently, we showed that high glucose induces changes in the
biophysical properties of the cardiac voltage-gated sodium channel (Nav1.5) that could be
strongly correlated to diabetes-induced arrhythmia. However, the mechanisms underlying
hyperglycemia-induced inflammation, and how inflammation provokes cardiac arrhythmia,
are not well understood. We hypothesized that inflammation could mediate the high
glucose-induced biophyscial changes on Nav1.5 through protein phosphorylation by
protein kinases A and C. We also hypothesized that this signaling pathway is, at least
partly, involved in the cardiprotective effects of cannabidiol (CBD) and 17β-estradiol (E2).
Methods and Results: To test these ideas, we used Chinese hamster ovarian (CHO) cells
transiently co-transfected with cDNA encoding human Nav1.5 α-subunit under control, a
cocktail of inflammatory mediators or 100 mM glucose conditions (for 24 h). We used
electrophysiological experiments and action potential modeling. Inflammatory mediators,
similar to 100 mM glucose, right shifted the voltage dependence of conductance and
steady-state fast inactivation and increased persistent current leading to computational
prolongation of action potential (hyperexcitability) which could result in long QT3
arrhythmia. We also used human iCell cardiomyocytes derived from inducible
pluripotent stem cells (iPSC-CMs) as a physiologically relevant system, and they
replicated the effects produced by inflammatory mediators observed in CHO cells. In
addition, activators of PK-A or PK-C replicated the inflammation-induced gating changes
of Nav1.5. Inhibitors of PK-A or PK-C, CBD or E2 mitigated all the potentially deleterious
effects provoked by high glucose/inflammation.
Conclusion: These findings suggest that PK-A and PK-C may mediate the anti-
inflammatory effects of CBD and E2 against high glucose-induced arrhythmia. CBD, via
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Nav1.5, may be a cardioprotective therapeutic approach in diabetic postmenopausal
population.
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INTRODUCTION
Cardiovascular anomalies are strongly correlated with diabetes-
induced morbidity and mortality (Matheus et al., 2013). These
deleterious cardiovascular complications are mainly attributed to
hyperglycemia/high glucose (Pistrosch et al., 2011). There is also
a positive correlation between diabetes/high glucose and long QT
(LQT) syndrome (Grisanti, 2018; Fouda et al., 2020a). LQT
syndrome is a cardiac arrhythmogenic disorder, identified by a
prolongation of the Q-T interval. One cause of LQT syndrome is a
gain-of-function in cardiac sodium channels, as in LQT3
(Shimizu and Antzelevitch, 1999).
Oxidative stress and activation of pro-inflammatory pathways
are among the main pathways involved in diabetes/high glucose
evoked cardiovascular abnormalities (Rajesh et al., 2010). Cardiac
inflammation has a key role in the development of cardiovascular
anomalies (Adamo et al., 2020). Inhibition of inflammatory
signaling pathways ameliorate cardiac consequences (Adamo
et al., 2020). Ion channels are crucial players in inflammation-
induced cardiac abnormalities (Eisenhut and Wallace, 2011).
Voltage-gated sodium channels (Nav) underlie phase 0 of the
cardiac action potential (Balser, 1999; Ruan et al., 2009). Changes
in the biophysical properties of the primary cardiac sodium
channel, Nav1.5, are linked to diabetes induced cardiovascular
abnormalities (Yu et al., 2018; Fouda et al., 2020a). However, the
mechanisms underlying hyperglycemia-induced inflammation,
and how inflammation provokes cardiac dysfunction, are not
well understood.
Cannabidiol (CBD) is approved as an anti-seizure drug
(Barnes, 2006; Devinsky et al., 2017). CBD lacks adverse
cardiac toxicity and ameliorates diabetes/high glucose induced
deletrious cardiomyopathy (Cunha et al., 1980; Izzo et al., 2009;
Rajesh et al., 2010). Recently, we showed that CBD rescues the
biophysical substrate for LQT3 via direct inhibitory effects on
cardiac sodium ion channels and indirect anti-oxidant effects
(Fouda et al., 2020a). In addition, CBD inhibits the production of
pro-inflammatory cytokines in vitro and in vivo (Nichols and
Kaplan, 2020).
Gonadal hormones have crucial roles in the inflammatory
responses (El-Lakany et al., 2018; El-Lakany et al., 2020).
Estrogen (E2), the main female sex hormone, acts via genomic
and non-genomic mechanisms to inhibit inflammatory cascades
(Murphy et al., 2010). Clinically, postmenopausal females
exhibited higher levels of TNF-α in reponse to endotoxemia
compared with pre-menopausal women (Moxley et al., 2004).
Interestingly, E2 stabilizes Nav fast inactivation and reduces the
late sodium currents (Wang et al., 2010), similar to CBD effects
on Nav1.5 (Fouda et al., 2020a).
Here, we characterized the role of inflammation in high
glucose-induced biophyscial changes on Nav1.5. Second, we
found that changes in the biophysical properties of Nav1.5
may be, at least in part, mediated through protein
phosphorylation by protein kinases A and C. Finally, we show
that this signaling pathway may be, at least partly, involved in the
cardiprotective effects of CBD and E2.
MATERIALS AND METHODS
Cell Culture
Chinese hamster ovary cells (CHO) (RRID: CVCL_0214; passages
from 3–13) were grown at pH 7.4 in filtered sterile F12 (Ham’s)
nutrient medium (Life Technologies, Thermo Fisher Scientific,
Waltham, MA, United States), supplemented with 5% FBS and
maintained in a humidified environment at 37°C with 5%CO2. Cells
were transiently co-transfected with the human cDNA encoding the
Nav1.5 α-subunit, the β1-subunit, and eGFP. Transfection was done
according to the PolyFect (Qiagen, Germantown, MD,
United States) transfection protocol. A minimum of 8°h
incubation was allowed after each set of transfections. The cells
were subsequently dissociated with 0.25% trypsin–EDTA (Life
Technologies, Thermo Fisher Scientific) and plated on sterile
coverslips under normal (10 mM) or elevated glucose
concentrations (100mM) (Fouda et al., 2020a) or a cocktail of
inflammatory mediators (Akin et al., 2019) containing bradykinin
(1 µM), PGE-2 (10 µM), histamine (10 µM), 5-HT (10 µM), and
adenosine 5′-triphosphate (15 µM) for 24 h prior to
electrophysiological experiments. We used 10mM (control, and
the necessary concentration for cultured CHO cell viability) and
100mM glucose to ensure sufficiently large readout signals
throughout the study; we recognize these are not physiologically
relevant concentrations. It should be noted that hyperglycemia is the
most important factor in the onset and progress of diabetic
complications (Viskupicova et al., 2015). High glucose
concentrations are usually used as a model to mimic the in vivo
situation of hyperglycemia in diabetes (Viskupicova et al., 2015).
High glucose concentrations (up to 100mMof D-glucose) have been
used previously to mimic the human hyperglycemia based on the
used cell line (Viskupicova et al., 2015). 100mM glucose was used in
many studies and in different cell lines, including human
erythrocytes (incubation for 72 h) (Viskupicova et al., 2015),
human SH-SY5Y neuroblastoma cell line (Liu et al., 2019), and
neuronal PC 12 cells (Chen et al., 2016; Fouda and Abdel-Rahman,
2017). We have previously used the MTS cell viability assay to
optimize the glucose concentration that would mimic the diabetic/
hyperglycemia conditions in CHO cells (Fouda et al., 2020a).
Importantly, it should be noted that CHO cells endogenously
express the receptors for the abovementioned inflammatory
mediators (Fukushima et al., 1994; George et al., 1997; Zhang
et al., 2001; de Wilde et al., 2010).
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iCell Cardiomyocytes
Single vials containing ≥1 × 106 iCell cardiomyocytes (Fujifilm
Cellular Dynamics International, kit R1105, Madison, WI,
United States ) were thawed by immersing the frozen cryovial
in a 37°C water bath, transferring thawed iCell cardiomyocytes
into a 50°ml tube, and diluting themwith 10°ml of ice-cold plating
medium (iCell Cardiomyocytes PlatingMedium (iCPM); Fujifilm
Cellular Dynamics International, Madison, WI, United States)
(Ma et al., 2011). For single cell patch-clamp recordings, glass
coverslips were coated with 0.1% gelatin (Fujifilm Cellular
Dynamics International, Madison, WI, United States) and
placed into each well of a 24-well plate for an hour. This was
followed by adding 1°ml of iCPM containing 40,000–60,000 iCell
cardiomyocytes to each coverslip. Plated iCell cardiomyocytes
were at a low density to permit culture as single cells and were
stored in an environmentally controlled incubator maintained at
37°C and 7% CO2. After 48°h, iCPM was replaced with a cell
culture medium (iCell Cardiomyocytes Maintenance Medium
(iCMM); Fujifilm Cellular Dynamics International, Madison,WI,
United States), which was exchanged every other day with the
iCell cardiomyocytes maintained on cover slips for 4–21°days
before use (Ma et al., 2011). iCell cardiomyocytes were incubated
in a cocktail of inflammatory mediators (Akin et al., 2019)
containing bradykinin (1 µM), PGE-2 (10 µM), histamine
(10 µM), 5-HT (10 µM), and adenosine 5′-triphosphate
(15 µM) or the vehicle for 24 h prior to electrophysiological
experiments.
Electrophysiology
Whole-cell patch clamp recordings from Nav1.5 expressed in
CHO cells were made using an extracellular solution
composed of NaCl (140 mM), KCl (4 mM), CaCl2 (2 mM),
MgCl2 (1 mM), HEPES (10 mM). The extracellular solution
was titrated to pH 7.4 with CsOH. Pipettes were fabricated
with a P-1000 puller using borosilicate glass (Sutter
Instruments, CA, United States), dipped in dental wax to
reduce capacitance, then thermally polished to a resistance
of 1.0–1.5 MΩ. Pipettes were filled with intracellular solution,
containing: CsF (120 mM), CsCl (20 mM), NaCl (10 mM),
HEPES (10 mM) titrated to pH 7.4. Patch clamp recordings
on human iCell cardiomyocytes were made using an
extracellular solution composed of NaCl (50 mM), CaCl2
(1.8 mM), MgCl2 (1 mM), CsCl2 (110 mM), glucose
(10 mM), HEPES (10 mM) and nifedipine (0.001 mM) (Ma
et al., 2011). The extracellular solution was titrated to pH 7.4
with CsOH. Pipettes were fabricated with a P-1000 puller using
borosilicate glass (Sutter Instruments, CA, United States),
dipped in dental wax to reduce capacitance, then thermally
polished to a resistance of 2.0–3.5 MΩ. Pipettes were filled with
intracellular solution, containing: CsCl2 (135 mM), NaCl
(10 mM), CaCl2 (2 mM), EGTA (5 mM), HEPES (10 mM)
and Mg-ATP (5 mM) titrated to pH 7.2 with CsOH (Ma
et al., 2011).
All recordings were made using an EPC-9 patch-clamp
amplifier (HEKA Elektronik, Lambrecht, Germany) digitized
at 20 kHz via an ITC-16 interface (Instrutech, Great Neck,
NY, United States). Voltage clamping and data acquisition
were controlled using PatchMaster/FitMaster software (HEKA
Elektronik, Lambrecht, Germany) running on an Apple iMac
(Cupertino, California). Current was low-pass-filtered at 5 kHz.
Leak subtraction was automatically done using a p/4 procedure
following the test pulse. Gigaohm seals were allowed to stabilize
in the on-cell configuration for 1 min prior to establishing the
whole-cell configuration. Series resistance was less than 5 MΩ for
all recordings. Series resistance compensation up to 80%was used
when necessary. All data were acquired at least 5 min after
attaining the whole-cell configuration, and cells were allowed
to incubate 5 min after drug application prior to data collection.
Before each protocol, the membrane potential was
hyperpolarized to −130 mV for 197 ms to insure complete
removal of both fast-inactivation and slow-inactivation.
Leakage and capacitive currents were subtracted with a P/4
protocol. All experiments were conducted at 22°C.
Activation Protocols
To determine the voltage-dependence of activation, we measured
the peak current amplitude at test pulse voltages ranging from
−130 to + 80 mV in increments of 10 mV for 19 ms. Channel
conductance (G) was calculated from peak INa:
GNa  INa/(V − ENa) (1)
where GNa is conductance, INa is peak sodium current in response
to the command potential V, and ENa is the Nernst equilibrium
potential. The midpoint and apparent valence of activation were
derived by plotting normalized conductance as a function of test
potential. Data were then fitted with a Boltzmann function:
G/Gmax  1/{1 + exp[ − ze0(Vm − V1/2)/KT]} (2)
where G/Gmax is normalized conductance amplitude, Vm is the
command potential, z is the apparent valence, e0 is the elementary
charge, V1/2 is the midpoint voltage, k is the Boltzmann constant,
and T is temperature in K.
Steady-State Fast Inactivation Protocols
The voltage-dependence of fast-inactivation was measured by
preconditioning the channels to a hyperpolarizing potential of
−130 mV (to insure complete channel availability) and then
eliciting pre-pulse potentials that ranged from −170 to +
10 mV in increments of 10 mV for 500 ms, followed by a
10 ms test pulse during which the voltage was stepped to
0 mV. Normalized current amplitude as a function of voltage
was fit using the Boltzmann function:
I/Imax  1/{1 + exp[ − ze0(Vm − V1/2)/KT]} (3)
where Imax is the maximum test pulse current amplitude. z is
apparent valence, e0 is the elementary charge, Vm is the prepulse
potential, V1/2 is the midpoint voltage of SSFI, k is the Boltzmann
constant, and T is temperature in K.
Fast Inactivation Recovery
Channels were fast inactivated during a 500 ms depolarizing step
to 0 mV. Recovery was measured during a 19 ms test pulse to
0 mV following −130 mV (to insure complete channel
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availability) recovery pulse for durations between 0 and 1.024 s.
Time constants of fast inactivation were derived using a double
exponential equation:
I  Iss + α1 exp(−t/τ1) + α2 exp(−t/τ2) (4)
where I is current amplitude, Iss is the plateau amplitude, α1 and
α2 are the amplitudes at time 0 for time constants τ1 and τ2, and t
is time.
Persistent Current Protocols
Late sodium current was measured between 45 and 50 ms during
a 50 ms or between 145 and 150 ms during a 200 ms depolarizing
pulse to 0 mV from a holding potential of −130 mV (to insure
complete channel availability) on CHO cells or iCell
cardiomyocytes, respectively. Fifty pulses were averaged to
increase signal to noise ratio (Abdelsayed et al., 2015;
Abdelsayed et al., 2018).
Action Potential Modeling
Action potentials were simulated using a modified version of the
O’Hara-Rudy model programmmed in Matlab (O’Hara et al.,
2011, PLoS Comput. Bio). The code that was used to produce
model is available online from the Rudy Lab website (http://
rudylab.wustl.edu/research/cell/code/Allcodes.html). The modified
gating INa parameters were in accordance with the biophysical
data obtained from whole-cell patch-clamp experiments in this
study for various conditions. The model accounted for activation
voltage-dependence, steady-state fast inactivation voltage-
dependence, persistent sodium currents, and peak sodium
currents (compound conditions).
Drug Preparations
CBD was purchased from Toronto Research Chemicals
(Toronto, Ontario) in powder form. Other compounds (e.g.,
17β-estradiol (E2), bradykinin, PGE-2, histamine, 5-HT,
adenosine 5′-triphosphate, D-glucose, Gö 6983 (PKC
inhibitor), H-89 (PKA inhibitor), 8-(4-chlorophenylthio)
adenosine- 3′,5′-cyclic monophosphate (CPT-cAMP; PKA
activator) or PMA (PKC activator)) were purchased from
Sigma-Aldrich (ON, Canada). Powdered CBD, Gö 6983, H-
89, adenosine CPT-cAMP or PMA were dissolved in 100%
DMSO to create stock and kept frozen until use. The stock was
used to prepare drug solutions in extracellular solutions at
various concentrations, immediately prior to perfusion, with
no more than 0.5% total DMSO content [which has no effect
on sodium currents (Ghovanloo et al., 2018; Fouda et al.,
2020a)]. Stock solution of E2 (1 mM) was prepared in
phosphate buffered saline (PBS) to be freshely diluted to 5
or 10 µM using the external solution in the day of the
electrophysiological experiment.
Data Analysis and Statistics
Studies were designed to generate groups of almost equal size (n 
5), using randomization and blinded analysis. Normalization was
performed in order to control the variations in sodium channel
expression and inward current amplitude and in order to be able
to fit the recorded data with Boltzmann function (for voltage-
dependences) or an exponential function (for time courses of
inactivation). Fitting and graphing were done using FitMaster
software (HEKA Elektronik, Lambrecht, Germany) and Igor Pro
(Wavemetrics, Lake Oswego, OR, United States). Statistical
analysis consisted of one-way ANOVA (endpoint data) along
with post hoc testing of significant findings along with Student’s
t-test and Tukey’s test using Prism 7 software (Graphpad
Software Inc., San Diego, CA, United States). Values are
presented as mean ± SEM with probability levels less than
0.05 considered significant. Statistical analysis was undertaken
only for studies where each group size was at least “n  5.” The
declared group size is the number of independent values, and that
statistical analysis was done using these independent values. In
the electrophysiological experiments, we randomized the
different treatments under the different conditions (e.g.,
control vs. high glucose or inflammatory mediators), so that
five cells in each treatment or condition came from five different
randomized cell passages.
RESULTS
Inflammatory Mediators Alter the Gating
Properties of Nav1.5 Similar to High
Glucose
We recently showed that high glucose, in a concentration-
dependent manner, right-shifts the voltage dependence of
activation and steady-state fast inactivation and increases
persistent current (Fouda et al., 2020a). Here, we used whole-
cell voltage-clamp to measure gating in human Nav1.5, and test
the effects of incubating for 24 h in either a cocktail of
inflammatory mediators (Akin et al., 2019) or 100 mM glucose
(Fouda et al., 2020a). Peak channel conductance was measured
between −130 and + 80 mV. We measured channel conductance
in the presence of inflammatory mediators to determine whether
the high glucose induced-changes in Nav1.5 activation (Fouda
et al., 2020a) are, at least partly, mediated through inflammation.
Figures 1A,B show the conductance plotted as a function of
membrane potential and the current-voltage (IV) curve,
respectively. High glucose (100 mM) significantly shifted the
Nav1.5 midpoint (V1/2) of activation in the positive direction
(p  0.0002). Additionally, the slope (apparent valence, z) of the
activation curves showed a significant decrease in 100 mM
glucose (p  0.007) (Figure 1A; Table 1). This decrease in
slope suggests a reduction in activation charge sensitivity. We
found that incubation in inflammatorymediators for 24 h, similar
to 100 mM glucose, significantly right-shifted V1/2 of activation
(p  0.001) and decreased z of activation curve (p  0.03)
(Figure 1A; Table 1). This suggests that both 100 mM glucose
or inflammatory mediators decrease the probability of Nav1.5
activation.
The DIII-IV linker mediates fast inactivation within a few
milliseconds of Nav activation (West et al., 1992). Figure 1C
shows normalized current amplitudes plotted as a function of
pre-pulse potential. 100 mM glucose or inflammatory
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mediators caused significant shifts in the positive direction in
the V1/2 obtained from Boltzmann fits (100 mM glucose: p <
0.0001; inflammatory mediators: p  0.001) (Figure 1C;
Table 2). These shifts indicate a loss-of-function in fast
inactivation and suggest that high glucose or inflammatory
mediators decrease the probability of steady-state fast
inactivation (SSFI) in Nav1.5.
To measure fast inactivation recovery, we held channels at
−130 mV to ensure channels were fully at rest, then depolarized
the channels to 0 mV for 500 ms, and allowed different time
intervals at −130 mV to measure recovery as a function of time.
We found that incubation in 100 mM glucose or inflammatory
mediators significantly (p < 0.05) increase the slow component of
fast inactivation recovery when compared to control, without
affecting the fast component of recovery (Figure 1D; Table 3).
An increased persistent sodium current (INap) is a
manifestation of destabilized fast inactivation (Goldin,
2003). Large INap is associated with a range of pathological
conditions, including LQT3 (Wang et al., 1995; Ghovanloo
et al., 2016). To determine the effects of glucose or
FIGURE 1 | (A) Effect of a cocktail of inflammatory mediators or 100 mM glucose or their vehicle (for 24 h) on conductance curve of Nav1.5 transfected CHO cells
with the insert showing the protocol (n  5, each). (B) IV curves (C) Effect of a cocktail of inflammatory mediators or 100 mM glucose or their vehicle (for 24 h) on SSFI of
Nav1.5 transfected CHO cells with the insert showing the protocol (n  5, each). (D) Effect of a cocktail of inflammatory mediators or 100 mM glucose or their vehicle (for
24 h) on recovery from fast inactivation of Nav1.5 transfected CHO cells with the insert showing the protocol (n  5, each). (E) Effect of a cocktail of inflammatory
mediators or 100 mM glucose or their vehicle (for 24 h) on the percentage of persistent sodium currents of Nav1.5 transfected CHO cells with the insert showing the
protocol (n  5, each). (F) Representative families of macroscopic currents. (G) In silico action potential duration of Nav1.5 transfected CHO cells incubated in
inflammatory mediators or 100 mM glucose or the vehicle for 24 h. (H) Representative persistent currents across conditions. Currents were normalized to peak current
amplitude. Bar above current traces indicates period during which persistent current was measured. Inset shows non-normalized currents. *p < 0.05 vs. corresponding
“Control” values using one-way ANOVA along with post hoc testing.
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inflammatory mediators on the stability of Nav1.5
inactivation, we held channels at −130 mV, followed by a
depolarizing pulse to 0 mV for 50 ms (Abdelsayed et al.,
2015; Abdelsayed et al., 2018). Figure 1E shows that
incubation in 100 mM glucose or inflammatory mediators
significantly increased INap compared to control (100 mM
TABLE 1 | Steady-state activation.
GV−V1/2 (mV) GV−z (slope) Current density (pA/pF) n
(at 0 mV)
Control
Control/Vehicle −36.2 ± 1.6 3.3 ± 0.2 −836.2 ± 83.1 5
Vehicle/H-89 −39.6 ± 1.4 3.2 ± 0.1 −832.5 ± 77.2 5
Vehicle/Gö 6983 −37.7 ± 0.7 3.1 ± 0.1 −877.3 ± 78.8 5
Glucose (100 mM)
100 mM glucose/Vehicle −16.6 ± 2.8 2.5 ± 0.1 −899.9 ± 115.7 5
Inflammatory mediators (IM)
IM/Vehicle −22.3 ± 2.4 2.7 ± 0.2 −761.8 ± 36.1 5
IM/H-89 −32.7 ± 1.4 2.8 ± 0.2 −661.8 ± 99.3 5
IM/Gö 6983 −31.7 ± 1.6 2.7 ± 0.1 −714.0 ± 116.9 5
CPT- cAMP −25.2 ± 0.5 2.5 ± 0.1 −697.3 ± 120.0 5
PMA −22.6 ± 1.6 2.5 ± 0.1 −797.2 ± 119.1 5
CBD (5 µM)
IM/CBD −39.1 ± 2.8 3.6 ± 0.1 −462.3 ± 32.7 5
CPT-cAMP/CBD −33.1 ± 0.6 3.4 ± 0.1 −414.6 ± 56.2 5
PMA/CBD −35.3 ± 0.9 3.3 ± 0.1 −437.5 ± 43.6 5
E2
E2 5°µM/vehicle −34.8 ± 1.5 3.1 ± 0.1 −709.5 ± 30.3 5
E2 10°µM/vehicle −34.3 ± 0.9 3.0 ± 0.1 −729.5 ± 49.3 5
E2 5°µM/glucose 100 mM −27.3 ± 0.7 2.4 ± 0.1 −856.3 ± 21.7 5
E2 10°µM/glucose 100 mM −37.9 ± 1.4 3.5 ± 0.1 −893.4 ± 71.8 5
E2 5°µM/IM −29.8 ± 1.3 2.8 ± 0.1 −730.2 ± 39.5 5
E2 10°µM/IM −35.7 ± 2.0 3.5 ± 0.1 −788.7 ± 28.5 5
E2 10°µM/CPT-cAMP −37.7 ± 0.6 3.6 ± 0.1 −760.2 ± 74.4 5
E2 10°µM/PMA −35.9 ± 1.5 3.4 ± 0.2 −808.5 ± 55.0 5
TABLE 2 | Steady-state fast inactivation.
SSFI−V1/2 (mV) SSFI−z (slope) n
Control
Control/Vehicle −90.9 ± 1.8 −2.6 ± 0.1 5
Vehicle/H-89 −89.3 ± 1.9 −2.7 ± 0.1 5
Vehicle/Gö 6983 −88.6 ± 2.1 −3.0 ± 0.1 5
Glucose (100 mM)
100 mM glucose/Vehicle −61.7 ± 2.6 −2.9 ± 0.1 5
Inflammatory mediators (IM)
IM/Vehicle −77.1 ± 1.7 −2.6 ± 0.1 5
IM/H-89 −86.4 ± 2.8 −2.9 ± 0.2 5
IM/Gö 6983 −87.1 ± 2.0 −2.4 ± 0.2 5
CPT-cAMP −79.4 ± 1.1 −3.0 ± 0.1 5
PMA −76.4 ± 1.7 −2.9 ± 0.2 5
CBD (5 µM)
IM/CBD −85.9 ± 1.5 −2.6 ± 0.3 5
CPT-cAMP/CBD −86.8 ± 2.3 −2.9 ± 0.2 5
PMA/CBD −85.7 ± 1.2 −2.9 ± 0.1 5
E2
E2 5°µM/vehicle −87.4 ± 2.1 −2.8 ± 0.1 5
E2 10°µM/vehicle −87.6 ± 2.1 −3.0 ± 0.2 5
E2 5°µM/glucose 100 mM −75.5 ± 1.9 −2.8 ± 0.2 5
E2 10°µM/glucose 100 mM −91.1 ± 3.6 −2.8 ± 0.1 5
E2 5°µM/IM −81.1 ± 2.1 −2.8 ± 0.1 5
E2 10°µM/IM −92.6 ± 0.8 −2.6 ± 0.1 5
E2 10°µM/CPT-cAMP −89.3 ± 1.9 −2.6 ± 0.1 5
E2 10°µM/PMA −88.7 ± 0.6 −2.3 ± 0.2 5
TABLE 3 | Time constants for the recovery from fast inactivation.
τ fast (s) τ slow (s) n
Control
Control/Vehicle 0.006 ± 0.001 0.006 ± 0.001 5
Vehicle/H-89 0.007 ± 0.001 0.006 ± 0.001 5
Vehicle/Gö 6983 0.006 ± 0.001 0.010 ± 0.002
Glucose (100 mM)
100 mM glucose/Vehicle 0.008 ± 0.002 0.111 ± 0.03 5
Inflammatory mediators (IM)
IM/Vehicle 0.005 ± 0.001 0.123 ± 0.002 5
IM/H-89 0.010 ± 0.002 0.303 ± 0.036 5
IM/Gö 6983 0.008 ± 0.002 0.304 ± 0.031 5
CPT- cAMP 0.006 ± 0.001 0.168 ± 0.009 5
PMA 0.005 ± 0.001 0.175 ± 0.005 5
CBD (5 µM)
IM/CBD 0.008 ± 0.001 0.209 ± 0.020 5
CPT-cAMP/CBD 0.009 ± 0.001 0.207 ± 0.004 5
PMA/CBD 0.006 ± 0.001 0.218 ± 0.014 5
E2
E2 5°µM/vehicle 0.006 ± 0.001 0.011 ± 0.002 5
E2 10°µM/vehicle 0.006 ± 0.001 0.010 ± 0.002 5
E2 5°µM/glucose 100 mM 0.005 ± 0.001 0.148 ± 0.009 5
E2 10°µM/glucose 100 mM 0.008 ± 0.002 0.228 ± 0.015 5
E2 5°µM/IM 0.005 ± 0.001 0.182 ± 0.015 5
E2 10°µM/IM 0.005 ± 0.001 0.262 ± 0.015 5
E2 10°µM/CPT-cAMP 0.007 ± 0.001 0.222 ± 0.008 5
E2 10°µM/PMA 0.007 ± 0.001 0.233 ± 0.006 5
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glucose: p < 0.0001; inflammatory mediators: p < 0.0001)
(Table 4). Representative families of macroscopic and
persistent currents across conditions are shown (Figures
1F,H). Notably, incubation in either high glucose (100 mM)
or inflammatory mediators for 24 h had no significant effect on
the current density of Nav1.5 when compared to the control
condition (Table 1).
We used the O’Hara-Rudy model to simulate cardiac
action potentials (AP) (O’Hara et al., 2011). The sodium
channel parameters in the model were modified using the
results of our experiments and the effects of the tested
compounds on the measured biophysical properties of
activation (midpoint and apparent valence), steady-state
fast inactivation (midpoint), recovery from fast
inactivation, and persistent sodium current amplitude. The
original model sodium channel parameters were adjusted to
correspond to the control results from the patch-clamp
experiments and the subsequent magnitude shifts in the
simulations, caused by other conditions, were adjusted
relative to the control parameters (Fouda et al., 2020a).
Figure 1G shows that modifying the model with sodium
channel parameters obtained from incubation in 100 mM
glucose or inflammatory mediators prolonged the simulated
AP duration (APD) from ∼300 to ∼500 ms (inflammatory
mediators) and to >600 ms (100 mM glucose). This increased
APD potentially leads to QT interval prolongation
(Nachimuthu et al., 2012). Despite the similarity between
100 mM glucose and inflammatory mediators-induced
changes on Nav1.5, their responses are not exactly the
same (Figure 1). This could be attributed to the
concentration-dependent effects of high glucose on
electrophysiological properties of Nav1.5 (Fouda et al., 2020a).
Activation of Protein Kinase A and Protein
Kinase C Mediates the Inflammatory
Mediators Induced Alteration in the Gating
Properties of Nav1.5
One of the key signaling pathways involved in inflammation is
the activation of protein kinase A or protein kinase C and
subsequent protein phosphorylation (Karin, 2005). To
pharmacologically investigate the role of PK-A or PK-C
signaling pathways in the inflammation-evoked gating
changes of Nav1.5, we recorded Nav1.5 currents at room
temperature in the absence, or after a 20 min perfusion, of
a PK-C activator [PMA; 10 nM (Hallaq et al., 2012)] or PK-A
activator [CPT-cAMP; 1 µM (Ono et al., 1993; Gu et al.,
2003)]. PMA or CPT-cAMP significantly shifted the
Nav1.5 V1/2 of activation in the positive direction (PMA:
p  0.0003; CPT-cAMP: p  0.0007) (Figure 2A; Table 1).
In addition, PMA or CPT-cAMP significantly reduced the
effective valence (z) of the activation curves (PMA: p  0.002;
CPT-cAMP: p  0.007) (Figure 2A; Table 1). Figure 1B shows
the IV curves. Furthermore, PMA or CPT-cAMP caused
significant right-shifts in the V1/2 of SSFI (PMA: p 
0.0008; CPT-cAMP: p  0.0005) (Figure 2C; Table 2).
Also, PMA or CPT-cAMP significantly (p < 0.05) increase
the slow component of fast inactivation recovery when
compared to control (Figure 2D; Table 3). We also found
that PMA or CPT-cAMP significantly (PMA: p < 0.0001;
CPT-cAMP: p < 0.0001) increased INap compared to
control (Figure 2E; Table 4). These effects are similar to
those of glucose and inflammatory mediators (Figure 1).
Representative families of macroscopic and persistent
currents across conditions are shown (Figures 2F,H).
Similar to 100 mM glucose and inflammatory mediators,
the data from PK-A (CPT-cAMP) or PK-C (PMA)
activator experiments shows that the in silico APD
increased from ∼300 ms to ∼400 ms (Figure 2G). PMA or
CPT-cAMP had no significant effect on the current density of
Nav1.5 when compared to the control condition (Table 1).
To ensure that the effects of the inflammatory mediators on
Nav1.5 are indeed mediated, at least partly, through activation
of PK-A and/or PK-C, we examined the effect of perfusing PK-
A inhibitor [H-89, 2 µM for 20 min (Wang et al., 2013)] or PK-
C inhibitor (Gö 6983, 1 µM for 20 min (Wang et al., 2013)) on
Nav1.5 that had been incubated for 24 h in either
inflammatory mediators or vehicle. Although H-89 or Gö
6983 had no significant effects on Nav1.5 gating under
control conditions (Supplementary Figure S1; Tables 1–4),
H-89 or Gö 6983 reduced the inflammatory mediator-induced
shifts in V1/2 (H-89: p  0.0108; Gö 6983: p  0.0203)
(Figure 3A; Table 1). Figure 3B shows IV curves. In
addition, H-89 or Gö 6983 rescued the inflammatory
mediator-induced shift in Nav1.5 SSFI (Figure 3C;
Table 2). Moreover, H-89 or Gö 6983 (p  0.0041, or p 
0.0017, respectively) further increased the time constant of the





Control/Vehicle 0.80 ± 0.05 5
Vehicle/H-89 0.82 ± 0.07 5
Vehicle/Gö 6983 0.84 ± 0.08 5
Glucose (100 mM)
100 mM glucose/Vehicle 6.86 ± 0.17 5
Inflammatory mediators (IM)
IM/Vehicle 3.64 ± 0.23 5
IM/H-89 1.21 ± 0.07 5
IM/Gö 6983 1.22 ± 0.06 5
CPT- cAMP 2.20 ± 0.08 5
PMA 2.18 ± 0.06 5
CBD (5 µM)
IM/CBD 0.93 ± 0.05 5
CPT-cAMP/CBD 1.04 ± 0.11 5
PMA/CBD 0.88 ± 0.07 5
E2
E2 5°µM/vehicle 0.85 ± 0.06 5
E2 10°µM/vehicle 0.91 ± 0.06 5
E2 5°µM/glucose 100 mM 1.92 ± 0.09 5
E2 10°µM/glucose 100 mM 0.89 ± 0.06 5
E2 5°µM/IM 1.73 ± 0.03 5
E2 10°µM/IM 0.85 ± 0.06 5
E2 10°µM/CPT-cAMP 0.95 ± 0.09 5
E2 10°µM/PMA 0.90 ± 0.11 5
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slow component of recovery from fast inactivation when
compared to inflammatory mediators (Figure 3D; Table 3).
Figure 3E shows that H-89 or Gö 6983 (p < 0.0001)
incompletely reduced the inflammatory mediator-induced
increase in the persistent currents (Table 4). Representative
families of macroscopic and persistent currents across
conditions are shown (Figures 3F,H ). Importantly, in silico
APD using the data from inhibitors of PK-A (H-89) or PK-C (Gö
6983) reduced the inflammatory mediators-induced simulated
APD prolongation (Figure 3G). H-89 or Gö 6983 had no
significant effect on the current density of Nav1.5 when
compared to the inflammatory or control conditions (Table 1).
Cannabidiol Rescues the Nav1.5 Gating
Changes of Inflammatory Mediators,
Activation of Protein Kinase A or Protein
Kinase C
Coupled with our previous observation that CBD rescues high
glucose-induced dysfunction in Nav1.5 (Fouda et al., 2020a), our
FIGURE 2 | (A) Effect of inflammatory mediators (for 24 h) or PK-A activator (CPT-cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) on
conductance curve Nav1.5 transfected CHO cells with the insert showing the protocol (n  5, each). (B) IV curves (C) Effect of inflammatory mediators (for 24 h) or PK-A
activator (CPT-cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) on SSFI of Nav1.5 transfected CHO cells with the insert showing the protocol (n  5,
each). (D) Effect of inflammatory mediators (for 24 h) or PK-A activator (CPT-cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) on recovery from
fast inactivation of Nav1.5 transfected CHO cells with the insert showing the protocol (n  5, each). (E) Effect of inflammatory mediators (for 24 h) or PK-A activator (CPT-
cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) on the percentage of persistent sodium currents of Nav1.5 transfected CHO cells with the insert
showing the protocol (n  5, each). (F) Representative families of macroscopic currents. (G) Effect of PK-A activator (CPT-cAMP; 1 µM for 20 min), PK-C activator (PMA;
10 nM, for 20 min) or inflammatory mediators (for 24 h) on the In silico action potential duration of Nav1.5 transfected CHO cells. (H) Representative persistent currents
across conditions. Currents were normalized to peak current amplitude. Bar above current traces indicates period during which persistent current was measured. Inset
shows non-normalized currents. *p < 0.05 vs. corresponding “Control” values using one-way ANOVA along with post hoc testing.
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results from the above experiments with PK-A or PK-C
modulators prompted us to test the effects of CBD on the
biophysical properties of Nav1.5 in the presence of
inflammatory mediators, PK-C activator (PMA), or PK-A
activator (CPT-cAMP). To determine whether the observed
changes to activation and SSFI imparted by inflammatory
mediators or activation of PK-A or PK-C could be rescued, we
measured peak sodium currents in the presence of CBD. CBD
concentration was selected based on its IC50 (Ghovanloo et al.,
2018). CBD (5 µM) perfusion abolished the effects of
inflammatory mediators, PMA, or CPT-cAMP, including shifts
of V1/2 of activation, z of activation, and the V1/2 of SSFI (Figures
4A–C; Tables 1 Tables 2). In addition, CBD significantly
increased the time constant of the slow component of recovery
from fast inactivation regardless of the concurrent treatment
(inflammatory mediators, PMA or CPT-cAMP) (Figure 4D;
Table 3). Also, CBD significantly (p < 0.0001) reduced the
increase in INap caused by inflammatory mediators
(Figure 4E; Table 4). Also, CBD significantly (p < 0.0001)
reduced PMA or CPT-cAMP-induced increase in INap
(Figure 4E; Table 4, with representative macroscopic and
persistent currents shown in Figures 4F,H). The O’Hara-Rudy
FIGURE 3 | (A) Effect of PK-A inhibitor (H-89, 2 µM for 20 min) or PK-C inhibitor (Gö 6,983, 1 µM for 20 min) or their vehicle on the conductance curve Nav1.5
transfected CHO cells incubated in the inflammatory mediators for 24 h with the insert showing the protocol (n  5, each). (B) IV curves (C) Effect of PK-A inhibitor (H-89,
2 µM for 20 min) or PK-C inhibitor (Gö 6,983, 1 µM for 20 min) or their vehicle on SSFI of Nav1.5 transfected CHO cells incubated in the inflammatory mediators for 24 h
with the insert showing the protocol (n  5, each). (D) Effect of PK-A inhibitor (H-89, 2 µM for 20 min) or PK-C inhibitor (Gö 6,983, 1 µM for 20 min) or their vehicle on
recovery from fast inactivation of Nav1.5 transfected CHO cells incubated in the inflammatory mediators for 24 h with the insert showing the protocol (n  5, each). (E)
Effect of PK-A inhibitor (H-89, 2 µM for 20 min) or PK-C inhibitor (Gö 6,983, 1 µM for 20 min) or their vehicle on the percentage of persistent sodium currents of Nav1.5
transfected CHO cells incubated in the inflammatory mediators for 24 h with the insert showing the protocol (n  5, each). (F) Representative families of macroscopic
currents. (G) Effect of PK-A inhibitor (H-89, 2 µM for 20 min) or PK-C inhibitor (Gö 6,983, 1 µM for 20 min) on the In silico action potential duration of Nav1.5 transfected
CHO cells incubated in inflammatory mediators for 24 h. (H) Representative persistent currents across conditions. Currents were normalized to peak current amplitude.
Bar above current traces indicates period during which persistent current was measured Inset shows non-normalized currents. *p < 0.05 vs. corresponding “Control/
Veh” values using one-way ANOVA along with post hoc testing. #p < 0.05 vs. corresponding “inflammatory mediators/Veh” values using Student’s t-test.
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model results also suggest that CBD rescues the prolonged in
silicoAPD caused by inflammatory mediators or activators of PK-
A or PK-C to nearly that of the control condition (Figure 4G).
The reduction in APD is consistent with the anti-excitatory
effects of CBD (Ghovanloo et al., 2018). CBD significantly
(p < 0.05) reduced the current density of Nav1.5 when
compared to the inflammatory or control conditions (Table 1).
To validate the protective effects of CBD against
inflammatory mediator-induced changes observed in the
CHO cells, we used hIPSC-CMs to confirm these effects.
Figures 5A,B show conductance plotted as a function of
membrane potential and the IV curves, respectively. We
found that incubation in inflammatory mediators for 24 h
significantly right-shifted V1/2 of activation (p  0.0015)
(from −37.3 ± 1.2 to −22.3 ± 2.4 mV, n  5, each) and
decreased z of activation curve (p  0.0034) (from 3.8 ± 0.16
to 2.7 ± 0.17 mV, n  5, each). Figure 5C shows normalized
current amplitudes plotted as a function of pre-pulse potential.
Inflammatory mediators caused significant shifts in the positive
direction in the V1/2 obtained from Boltzmann fits (p  0.0084)
(from −92.3 ± 3.4 to −77.1 ± 1.7 mV, n  5, each). To determine
the effects of inflammatory mediators on the stability of Nav1.5
FIGURE 4 | (A) Effect of CBD (5 μM, perfusion) on the conductance curve of Nav1.5 transfected CHO cells incubated with inflammatory mediators (24 h) or PK-A
activator (CPT-cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) with the insert showing the protocol (n  5, each). (B) IV curves (C) Effect of CBD
(5 μM, perfusion) on SSFI of Nav1.5 transfected CHO cells incubated with inflammatory mediators (24 h) or PK-A activator (CPT-cAMP; 1 μM, for 20 min) or PK-C
activator (PMA; 10 nM, for 20 min) with the insert showing the protocol (n  5, each). (D) Effect of CBD (5 μM, perfusion) on recovery from fast inactivation of Nav1.5
transfected CHO cells incubated with inflammatory mediators (24 h) or PK-A activator (CPT-cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) with the
insert showing the protocol (n  5, each). (E) Effect of CBD (5 μM, perfusion) on the percentage of persistent sodium currents of Nav1.5 transfected CHO cells incubated
with inflammatory mediators (24 h) or PK-A activator (CPT-cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) with the insert showing the protocol (n 
5, each). (F)Representative families of macroscopic currents. (G) Effect of CBD (5 μM, perfusion) on the In silico action potential duration of Nav1.5 transfected CHO cells
incubated in inflammatory mediators (24 h) or PK-A activator (CPT-cAMP; 1 μM, for 20 min) or PK-C activator (PMA; 10 nM, for 20 min). (H) Representative persistent
currents across conditions. Currents were normalized to peak current amplitude. Bar above current traces indicates period during which persistent current was
measured. Inset shows non-normalized currents. *p < 0.05 vs. corresponding “Control/Veh” values using one-way ANOVA along with post hoc testing.
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inactivation, we held channels at −130 mV, followed by a
depolarizing pulse to 0 mV for 200 ms. Figure 5D shows that
incubation in inflammatory mediators significantly increased
INap compared to control (inflammatory mediators: p < 0.0001)
(from 0.80 ± 0.05 to 5.44 ± 0.11, n  5, each). While CBD had no
significant effect on INap under control condition, it
significantly (p  0.0144) reduced the inflammatory
mediators-induced increase in INap (Figure 5D). Figure 5E
shows that modifying the model with data obtained from
incubation in inflammatory mediators prolonged the
simulated AP duration (APD) from ∼300 ms to ∼500 ms.
This increased APD potentially leads to the prolongation of
the QT interval (Nachimuthu et al., 2012). Representative
families of macroscopic and persistent currents across
conditions are shown (Figures 5F,G).
17β-Estradiol Rescues the High
Glucose-Induced Alterations in Nav1.5
Gating via Protein Kinase A and Protein
Kinase C Pathway
We further investigated whether E2 rescues the high-glucose
induced changes in biophysical properties of Nav1.5 given that
E2 previously was shown to affect Nav in addition its anti-
FIGURE 5 | (A) Effect of CBD (5 μM, perfusion) or its vehicle on the conductance curve measured from human iCell cardiomyocytes (hIPSC-CMs) incubated with
inflammatory mediators (24 h) or their vehicle with the insert showing the protocol (n  5, each). (B) IV curves (C) Effect of CBD (5 μM, perfusion) or its vehicle on SSFI of
human iCell cardiomyocytes (hIPSC-CMs) incubated with inflammatory mediators (24 h) or their vehicle with the insert showing the protocol (n  5, each). (D) Effect of
CBD (5 μM, perfusion) or its vehicle on the percentage of persistent sodium currents of human iCell cardiomyocytes (hIPSC-CMs) incubated with inflammatory
mediators (24 h) or their vehicle with the insert showing the protocol (n  5, each). (E) Effect of CBD (5 μM, perfusion) or its vehicle on the In silico action potential duration
of human iCell cardiomyocytes (hIPSC-CMs) incubated in inflammatory mediators (24 h) or their vehicle. (F) Representative families of macroscopic currents. (G)
Representative persistent currents across conditions. Currents were normalized to peak current amplitude. Bar above current traces indicates period during which
persistent current was measured. Inset shows non-normalized currents. *p < 0.05 vs. corresponding “Control” values using one-way ANOVA along with post hoc
testing.
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inflammatory role (Wang et al., 2010; Iorga et al., 2017). We first
tested the effects of E2 (5 or 10 µM) under control conditions and
found that E2 exerted no significant effects on Nav1.5 gating
(Supplementary Figure S1; Tables 1–4). In contrast, Figure 6
shows that perfusing E2 (5 or 10 µM) for at least 10 min into the
bath solution (Möller and Netzer, 2006; Wang et al., 2013)
abolished the shifts elicited by high glucose (100 mM, for 24 h,
including V1/2, z of activation, and the V1/2 of SSFI in a
concentration-dependent manner (Figures 6A–C; Tables 1, 2).
On the other hand, we found that E2 (5 or10 µM) had no
significant effect on 100 mM glucose-induced slight increase in
the slow component of fast inactivation recovery (Figure 6D;
Table 3). However, E2 significantly reduced the 100 mM glucose-
induced increase in INap in a concentration-dependent manner
(Figure 6E; Table 4). E2 reduction of the glucose-exacerbated
INap is consistent with previous reports of similar effects in
neuronal sodium channels (Wang et al., 2010). Figure 6G shows
AP modeling and suggests that E2, in a concentration-dependent
manner, rescues the prolonged in silico APD caused by 100 mM
glucose. Representative families of macroscopic and persistent
currents across conditions are shown (Figures 6F,G). E2 (5
or10 µM) had no significant effect on the current density of
FIGURE 6 | (A) Effect of E2 (5 or 10 µM) on conductance curve of Nav1.5 transfected CHO cells incubated in 100 mM glucose (for 24 h) with the insert showing the
protocol (n  5, each). (B) IV curves (C) Effect of E2 (5 or 10 µM) on SSFI of Nav1.5 transfected CHO cells in 100 mM glucose (for 24 h) with the insert showing the
protocol (n  5, each). (D) Effect of E2 (5 or 10 µM) on recovery from fast inactivation of Nav1.5 transfected CHO cells in 100 mMglucose (for 24 h) with the insert showing
the protocol (n  5, each). (E) Effect of E2 (5 or 10 µM) on the percentage of persistent sodium currents of Nav1.5 transfected CHO cells in 100 mM glucose (for
24 h) with the insert showing the protocol (n  5, each). (F) Representative families of macroscopic currents. (G) Effect of E2 (5 or 10 µM) on the In silico action potential
duration of Nav1.5 transfected CHO cells incubated in 100 mM glucose (for 24 h). (H)Representative persistent currents across conditions. Currents were normalized to
peak current amplitude. Bar above current traces indicates period during which persistent current was measured. Inset shows non-normalized currents. *p < 0.05 vs.
corresponding “Control/Veh” values using one-way ANOVA along with post hoc testing. #p < 0.05 vs. corresponding “100 mM glucose/Veh” values using Student’s
t-test.
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Nav1.5 when compared to the control condition or 100 mM
glucose (Table 1).
We tested whether E2 (5 or 10 µM) rescues the effects of
inflammatory mediators, PK-C activator (PMA), or PK-A
activator (CPT-cAMP) on the gating properties of Nav1.5.
Figure 7 shows that concurrent addition of E2 abolished the
effects of inflammatory mediators on activation and SSFI in a
concentration-dependent manner (Figures 7A–C; Tables 1, 2).
Similiarly, E2 concentration-dependently rescued PMA or CPT-
cAMP-elicited effects on activation and SSFI (Figures 7A–C;
Table 1, 2). Although E2 (5 or10 µM) had no significant effect on
the slight increase in the slow component of fast inactivation
recovery caused by inflammatory mediators, PMA, or CPT-
cAMP (Figure 7D; Table 3), E2 significantly reduced the
increase in INap in a concentration-dependent manner
(Figure 7E; Table 4; representative currents shown in Figures
7F,H). In addition, E2 concentration-dependently rescues the
prolonged in silico APD caused by inflammatory mediators or
activators of PK-A or PK-C-induced to nearly that of the control
condition (Figure 7G). E2 (5 or 10 µM) had no significant effect
FIGURE 7 | (A) Effect of E2 (5 or 10 µM) on conductance curve of Nav1.5 transfected CHO cells incubated in inflammatory mediators (for 24 h), PK-A activator
(CPT-cAMP; 1 µM for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) with the insert showing the protocol (n  5, each). (B) IV curves (C) Effect of E2 (5 or 10 µM) on
SSFI of Nav1.5 transfected CHO cells incubated in inflammatory mediators (for 24 h), PK-A activator (CPT-cAMP; 1 µM for 20 min) or PK-C activator (PMA; 10 nM, for
20 min) with the insert showing the protocol (n  5, each). (D) Effect of E2 (5 or 10 µM) on recovery from fast inactivation of Nav1.5 CHO transfected cells incubated
in inflammatory mediators (for 24 h), PK-A activator (CPT-cAMP; 1 µM for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) with the insert showing the protocol (n  5,
each). (E) Effect of E2 (5 or 10 µM) on the percentage of persistent sodium currents of Nav1.5 transfected CHO cells incubated in inflammatory mediators (for 24 h), PK-A
activator (CPT-cAMP; 1 µM for 20 min) or PK-C activator (PMA; 10 nM, for 20 min) with the insert showing the protocol (n  5, each). (F) Representative families of
macroscopic currents. (G) Effect of E2 (5 or 10 µM) on the In silico action potential duration of Nav1.5 transfected cells incubated in inflammatory mediators (for 24 h), PK-
A activator (CPT-cAMP; 1 µM for 20 min) or PK-C activator (PMA; 10 nM, for 20 min). (H) Representative persistent currents across conditions. Currents were
normalized to peak current amplitude. Bar above current traces indicates period during which persistent current was measured. Inset shows non-normalized currents.
*p < 0.05 vs. corresponding “Control/Veh” values using one-way ANOVA along with post hoc testing. #p < 0.05 vs. corresponding “inflammatory mediators/Veh” values
using Student’s t-test.
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on the current density of Nav1.5 when compared to the control
condition or the inflammatory mediaitors (Table 1).
DISCUSSION
We recently showed that CBD confers protection on Nav1.5
against the high glucose-elicited hyperexictability and
cytotoxicity (Fouda et al., 2020a). Here, we address, for the
first time, the inflammation/PK-A and PK-C signaling
pathway to mediate high glucose-induced cardiac anomalies
(Figure 8). Our results suggest that CBD and E2 may exert
their cardioprotective effects against high glucose, at least
partly, through this signaling pathway. Our conclusions are
based on the following observations: 1) Similar to high
glucose, inflammatory mediators elicited right shifts in the
voltage-dependence of activation and inactivation, and
exacerbated persistent currents. Increased persistent currents
prolong the simulated action potential duration. 2) Activators
of PK-A and PK-C reproduced the high glucose- and
inflammation-induced changes in Nav1.5 gating. 3) Inhibitors
of PK-A and PK-C reduced, to a great extent, the high glucose-
and inflammation-induced changes in Nav1.5 gating. 4) CBD or
E2 rescued the effects of high glucose, inflammatory mediators, or
PK-A or PK-C activators. Our results suggest a role for Nav1.5 in
high glucose induced hyperexcitability, via inflammation and
subsequent activation of PK-A and PK-C, which could lead to
LQT3-type arrhythmia (Figure 8). In addition, our findings
suggest possible therapeutic effects for CBD in high glucose-
provoked cardiac dysfunction in diabetic patients, especially
those post-menopause.
Diabetes-induced QT prolongation predisposes to malignant
ventricular arrhythmias (Ukpabi and Onwubere, 2017).
Moreover, LQT in diabetic patients make them three times
more vulnerable to the risk of cardiac arrest (Whitsel et al.,
2005). Nav1.5 gain-of-function plays a crucial role in the
development of LQT (Shimizu and Antzelevitch, 1999). With
that in mind, we found that inflammatory mediators replicated
the high glucose-induced changes in Nav1.5 gating similar to
those correlated with LQT3 in diabetic rats (Yu et al., 2018). This
finding is consistent with other reports showing that
hyperglycemia/high glucose is proinflammatory and that
inflammation is a crucial player in the pathogenesis of
cardiovascular anamolies (Tsalamandris et al., 2019; Fouda
et al., 2020b). Accumulating evidence shows that inflammation
is a potential cause for developing LQT through direct effects on
myocardial electric properties, including its effect on Nav, and
indirect autonomic cardiac regulations (Lazzerini et al., 2015).
Inflammation alters the electrophysiological properties of iCell
cardiomyocytes Nav with an increase in INap leading to
prolongation of APD, similar to our findings (Figure 1)
(Ward et al., 2006; Shryock et al., 2013). Taken together, these
findings support our hypothesis that high glucose, at least partly
through induction of inflammation, alters Nav1.5 gating and
leads to LQT arrhythmia (Figure 8).
The activation of PK-A and PK-C and subsequent protein
phosphorylation are among the key signaling pathways associated
with inflammation (Karin, 2005) and hyperglycemia, resulting in
many devastating diabetes-induced cardiac complications (Koya and
King, 1998; Bockus and Humphries, 2015). Our data suggest that
activation of PK-A or PK-C replicated high glucose- and
inflammation-induced gating changes in Nav1.5 gating, whereas
inhibition of PK-A or PK-C abolished those changes (Figures 2, 3).
This finding suggests that PK-A and PK-C may be downstream
effectors of inflammation in high glucose-induced cardiac
complications (Figure 8). PK-A phosphorlylates S525 and S528,
while PK-C phosphorylates S1503 in human Nav1.5 (Iqbal and
Lemmens-Gruber, 2019). There are conflicting reports regarding the
effects of PK-A and PK-C activation on the voltage-dependence and
kinetics of Nav1.5 gating. These differences could be attributed to
different voltage protocols, different holding potentials, different
concentrations or type of PK-activators, or different cell lines used in
the various studies (Aromolaran et al., 2018; Iqbal and Lemmens-
Gruber, 2019). Despite these discrepancies, both PK-A or PK-C
destabilize Nav fast inactivation and hence increase INap, which is
strongly correlated to prolonged APD as shown in our findings
(Figure 8) (Astman et al., 1998; Franceschetti et al., 2000; Tateyama
et al., 2003).
Our results with PK-A and PK-C modulators prompted us to
test whether CBD affects the biophysical properties of Nav1.5
through this pathway. Notably, CBD has little to no affinity for
endocannabinoid receptors (Thomas et al., 1998). We
investigated the possible protective effect of CBD against the
deletrious effects of high glucose through this signaling pathway
because CBD protects against high glucose-induced gating
changes in Nav1.5 (Fouda et al., 2020a). In addition, CBD
attenuates the diabetes-induced inflammation and subsequent
cardiac fibrosis through inhibition of phosphorylation enzymes
(such as MAPKs) (Rajesh et al., 2010). Our results suggest that
CBD alleviates the inflammation/activation of PK-A or PK-C
induced biophyscial changes (Figure 4). Our findings are
consistent with the anti-inflammatory, anti-oxidant, and anti-
tumor effects of CBD via inhibition of PK-A and PK-C signaling
FIGURE 8 | A schematic of possible cellular pathway involved in the
protective effect of CBD, E2 against high glucose induced inflammation and
activation of PK-A and PK-C via affecting cardiac voltage-gated sodium
channels (Nav1.5).
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(Seltzer et al., 2020). The incomplete protective effects of PK-A
and PK-C inhibitors compared to the CBD effect against the
inflammation-induced gating changes in Nav1.5 could be
attributed to the direct inhibitory effect CBD has on Nav1.5
(Ghovanloo et al., 2018; Fouda et al., 2020a), among other
possible contributing pathways, including phosphorylation.
These potential mechanisms need further investigation.
Interestingly, E2 directly inhibits Nav and exerts anti-inflammatory
effects (Wang et al., 2010; Iorga et al., 2017). We found that E2, similar
to CBD, rescues the effects of high-glucose, inflammation, and
activation of PK-A or PK-C (Figures 6–8). Our results are
consistent with other reports showing the cardioprotective effects of
E2 by increasing angiogenesis, vasodilation, and decreasing oxidative
stress and fibrosis (Iorga et al., 2017). Although the role of E2 in
arrhythmias is controversial, many studies support the anti-arrythmic
effects of E2 because of its effects on the expression and function of
cardiac ion channels (Odening and Koren, 2014; Iorga et al., 2017).
Notably, E2 stabilizes Nav fast inactivation and reduces INap, similar to
CBD (Wang et al., 2010). Further, E2 reduces the oxidative stress and
the inflammatory reponses by inhibiting PK-A and PK-C-mediated
signaling pathways (Viviani et al., 2002; Mize et al., 2003). Notably,
CHO cells endogenously express E2 receptors alpha and beta (Thomas
et al., 2003). It is important to note that E2 activates intracellular signals
by two pathways: genomic (Hall and Korach, 2002) or nongenomic
activation (Watson et al., 2007). E2 binds to the intracellular E2
receptors (ERs) in the cytosol or nucleus controling the gene
expression in the genomic pathway while it activates fast
intracellular signals through the non-genomic pathway (Zhang
et al., 2012). E2 affects the ion channel function via a non-genomic
mechanism such as transient receptor potential vanilloid receptor 1 (Xu
et al., 2008), calcium channels (Lee et al., 2002) and Nav (Wang et al.,
2013). In addition, our findings are consistent with others showing that
E2 affects Nav in a concentration-dependent, rapid, reversible manner
and dependent on a PKC–PKA signaling pathway (Wang et al., 2013).
Our results suggest that inflammation and the subsequent
activation of PK-A and PK-C correlates with the high glucose-
induced electrophysiological changes in Nav1.5 gating (Figure 8).
Future studies may determine whether there is a causal
relationship between elevated glucose and PK-A and/or PK-C
mediated channel phosphorylation. In silico, these gating changes
result in prolongation of simulated action potentials leading to
LQT3 arrhythmia, which is a clinical complication of diabetes
(Grisanti, 2018). A caveat of the AP modeling is that only sodium
channel properties were modified. The properties of other
channels were left unchanged even though previous reports
show they are affected by the experimental parameters (Ali
et al., 2015; Le Marois et al., 2020; Orvos et al., 2020).
In conclusion, CBD and E2, through inhibition of the PK-A
and PK-C signaling pathways, appear to ameliorate the effects of
high glucose and the resultant clinical condition. In light of the
debate about the risks associated with hormonal replacement
therapy (Climént-Palmer and Spiegelhalter, 2019), CBD may
provide an alternate therapeutic approach, especially in
diabetic post-menopausal populations due to their decreased
levels of cardioprotective E2 (Xu et al., 2014).
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